Amy Gravell

507 total citations
10 papers, 302 citations indexed

About

Amy Gravell is a scholar working on Molecular Biology, Oncology and Statistics and Probability. According to data from OpenAlex, Amy Gravell has authored 10 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Oncology and 3 papers in Statistics and Probability. Recurrent topics in Amy Gravell's work include Statistical Methods in Clinical Trials (3 papers), Cancer Genomics and Diagnostics (2 papers) and Biomedical and Engineering Education (1 paper). Amy Gravell is often cited by papers focused on Statistical Methods in Clinical Trials (3 papers), Cancer Genomics and Diagnostics (2 papers) and Biomedical and Engineering Education (1 paper). Amy Gravell collaborates with scholars based in United States and Canada. Amy Gravell's co-authors include Susan Groshen, Mark J. Ratain, Ralph E. Parchment, Janet Dancey, Lalitha Shankar, Walter M. Stadler, Kevin K. Dobbin, J. Milburn Jessup, María Koehler and Michael R. Grever and has published in prestigious journals such as Clinical Cancer Research, Frontiers in Medicine and JNCI Cancer Spectrum.

In The Last Decade

Amy Gravell

10 papers receiving 293 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy Gravell United States	6	151	90	82	66	40	10	302
Ariel B. Bourla United States	10	149 1.0×	124 1.4×	89 1.1×	141 2.1×	21 0.5×	17	397
Massimo Gion Italy	11	105 0.7×	101 1.1×	52 0.6×	153 2.3×	26 0.7×	24	303
Henry Hiep Vo United States	10	217 1.4×	169 1.9×	126 1.5×	93 1.4×	15 0.4×	15	495
Elsa Curtit France	11	216 1.4×	76 0.8×	115 1.4×	106 1.6×	38 0.9×	45	441
Amy Barone United States	9	217 1.4×	102 1.1×	61 0.7×	87 1.3×	9 0.2×	14	396
Karim Khetani Canada	7	249 1.6×	127 1.4×	109 1.3×	40 0.6×	66 1.6×	8	424
Kelly Y. Kim United States	8	167 1.1×	175 1.9×	122 1.5×	68 1.0×	47 1.2×	11	536
Elisa Rizzo Italy	6	190 1.3×	47 0.5×	76 0.9×	132 2.0×	38 0.9×	7	343
O. Rixe France	8	355 2.4×	89 1.0×	170 2.1×	128 1.9×	17 0.4×	16	482
N. Afonso Portugal	13	244 1.6×	106 1.2×	100 1.2×	86 1.3×	29 0.7×	28	495

Countries citing papers authored by Amy Gravell

Since Specialization

Citations

This map shows the geographic impact of Amy Gravell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Gravell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Gravell more than expected).

Fields of papers citing papers by Amy Gravell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Gravell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Gravell. The network helps show where Amy Gravell may publish in the future.

Co-authorship network of co-authors of Amy Gravell

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Gravell. A scholar is included among the top collaborators of Amy Gravell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Gravell. Amy Gravell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Paller, Channing J., Thomas Luechtefeld, Holly A. Massett, et al.. (2019). Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials. Frontiers in Medicine. 6. 122–122. 10 indexed citations

2.

Massett, Holly A., Jeffrey A. Moscow, Amy Gravell, et al.. (2019). Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN). Clinical Cancer Research. 25(23). 6925–6931. 6 indexed citations

3.

Girotra, Monica, Aaron R. Hansen, Azeez Farooki, et al.. (2018). The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. JNCI Cancer Spectrum. 2(3). pky021–pky021. 89 indexed citations

4.

Seymour, Lesley, Susan Groshen, Gary L. Rosner, et al.. (2015). Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clinical Cancer Research. 21(22). 5057–5063. 2 indexed citations

5.

Dancey, Janet, Kevin K. Dobbin, Susan Groshen, et al.. (2010). Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents. Clinical Cancer Research. 16(6). 1745–1755. 173 indexed citations

6.

Wright, James R., et al.. (2005). Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1.. PubMed. 19(4). 499–502. 8 indexed citations

7.

Colevas, Dimitrios, Barbara Blaylock, & Amy Gravell. (2002). Clinical trials referral resource. Flavopiridol.. PubMed. 16(9). 1204–5, 1210. 5 indexed citations

8.

Colevas, A. Dimitrios, Barbara Blaylock, & Amy Gravell. (2002). Current Clinical Trials of Flavopiridol. 1 indexed citations

9.

Wright, James R., Kenn L. Zerivitz, Amy Gravell, & Bruce D. Cheson. (2002). Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra).. PubMed. 16(7). 930–1, 935. 7 indexed citations

10.

Zwiebel, James A., et al.. (2001). Current Clinical Trials of Fenretinide. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact